Premium
Blood component use in critical care in patients with COVID‐19 infection: a single‐centre experience
Author(s) -
Doyle Andrew J.,
Danaee Anicee,
Furtado Charlene I.,
Miller Scott,
Maggs Tim,
Robinson Susan E.,
Retter Andrew
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17007
Subject(s) - cryoprecipitate , medicine , extracorporeal membrane oxygenation , covid-19 , fresh frozen plasma , pandemic , emergency medicine , blood component , intensive care medicine , blood product , apheresis , surgery , disease , platelet , infectious disease (medical specialty)
Summary There has been a significant surge in admissions to critical care during the coronavirus disease 2019 (COVID‐19) pandemic. At present, the demands on blood components have not been described. We reviewed their use during the first 6 weeks of the outbreak from 3 March 2020 in a tertiary‐level critical care department providing venovenous extracorporeal membrane oxygenation (vv‐ECMO). A total of 265 patients were reviewed, with 235 not requiring ECMO and 30 requiring vv‐ECMO. In total, 50 patients required blood components during their critical care admission. Red cell concentrates were the most frequently transfused component in COVID‐19‐infected patients with higher rates of use during vv‐ECMO. The use of fresh frozen plasma, cryoprecipitate and platelet transfusions was low in a period prior to the use of convalescent plasma.